Do GLP-1 Drugs Mask or Fuel Disordered Eating?[/TITLE>
I usually begin my obesity medicine appointments with a simple question: “How are you feeling today?” On this particular visit, the patient’s answer caught my attention—”I feel like the medication is finally working.”
A glance at the chart confirmed the progress: down 21 pounds in three months. Yet as a clinician, I’ve learned that rapid results on GLP-1 receptor agonists can sometimes conceal a more complicated story—one that raises an uncomfortable question about whether these drugs might mask, or even enable, disordered eating patterns.
Also Read
- FDA Approves Promega’s OncoMate Test as a Companion Diagnostic for Keytruda in MSI-High Solid Tumors
- Metformin Shows Promise in Long COVID Management; Lp(a) Reduction Emerges as Key Cardiovascular Strategy
- Illicit cigarettes at Sydney “clean beauty” launch prompt health investigation
- Virginia Confirms First Measles-Linked Death of 2026 in Young Child


